메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

[ 메디채널 김갑성 기자 ] Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain failure such as very low birth weight (VLBW) infants." The approval was supported by data from the pivotal Japan-based JASMINE Phase III clinical trial, a randomised, open-label, parallel-group comparison study in VLBW infants. This first-of-its kind approval set a new regulatory precedent, bridged innovati
- 김갑성 기자
- 2026-02-12 20:00
First clinical success! Yuanhua Tech, with its orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, breaks into the high-end medical equipment market

HONG KONG, Feb. 12, 2026 -- On February 11, the orthopaedic surgical robot with originally developed HX Orthopaedic-Specific Robotic Arm, which was 100% homemade by Yuanhua Robotics, Perception and AI Technologies Ltd. (hereinafter referred to as "Yuanhua Tech"), saw its first clinical success at West China Hospital of Sichuan University. This milestone achievement signifies that the domestically produced high-end surgical robot has successfully passed the clinical verification of a top medical institution in the field of self-developed key execution components. It has inject
- 김갑성 기자
- 2026-02-12 19:34
EDAN Connects Clinical Practice and Innovation at 2026 WHX Dubai and WHX Labs Dubai

DUBAI, UAE, Feb. 12, 2026 -- Edan Instruments, Inc. (300206.SZ) participated in WHX Dubai (Formerly Arab Health) and WHX Labs Dubai (Formerly Medlab Middle East), presenting a comprehensive portfolio of medical solutions across multiple clinical disciplines. With an expected attendance of over 235,000 visitors at WHX Dubai and 35,000 at WHX Labs Dubai, the two events brought together healthcare professionals, partners, and industry stakeholders from around the world. This year, WHX Dubai took place at Dubai's newly expanded venue, underscoring its continued growth as an international
- 김갑성 기자
- 2026-02-12 17:27
Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients

ZUG, Switzerland, Feb. 12, 2026 -- Berlin Heals Holding AG, a MedTech company focused on transformative therapies for heart failure, today announced the successful closing of a new financing round, raising over 10M USD from a combination of existing shareholders and new investors. The funding will be used to advance the company's cardiac microcurrent technology and expand its clinical research program. Berlin Heals has developed a novel therapeutic approach for the treatment of heart failure based on its proprietary implantable device, C-MIC (Cardiac Microcurrent). The system h
- 김갑성 기자
- 2026-02-12 16:00
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

SEOUL, South Korea, Feb. 12, 2026 -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). According to the most recent Journal Citation Reports (2025), the journal has an Impact Factor of 10.2, reflecting its influence in translational and clinical cancer research. The study presents a therapeutic strategy designed to overcome EGFR C797S, a major resistan
- 김갑성 기자
- 2026-02-12 15:01
Cathay Financial Ramps Up Regional Asset Management Ambitions Through Full Product Shelf, Talent and One-Stop Service Platform

TAIPEI, Feb. 12, 2026 -- As Taiwan's largest integrated asset management group, Cathay Financial Holdings (Cathay FHC) continues to expand its platform by leveraging more than six decades of investment expertise and over USD 325 billion in assets under management. Cathay FHC leverages its group-wide resources across three core growth engines—Banking, Insurance, and Asset Management. Both Cathay United Bank and Cathay Life Insurance are among the first batch of institutions approved to conduct pilot operations in the Kaohsiung Zone of the Asian Asset Management Center. This unde
- 황정호 기자
- 2026-02-12 14:22
AIA Singapore surpasses S$40 Billion in payouts over the last decade

[ 메디채널 김갑성 기자 ] Commemorating its 95th anniversary, the insurer reinforces its role as a vital safety net and wealth partner with new initiatives to fulfil promises across healthcare and long-term financial goals as well as deepen its engagement, contributing meaningfully to the nation's progress. SINGAPORE, Feb. 12, 2026 -- AIA Singapore today announced its 95th Anniversary, standing shoulder-to-shoulder with Singaporeans, building a vital safety net for families and fulfilling its promise by paying out billions in claims over the decades. In the last decade alone, AIA Singapore hav
- 김갑성 기자
- 2026-02-12 13:36
Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

SHANGHAI, Feb. 12, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis (IPF). This clearance enables ArkBio to initiate a Phase 2 proof-of-concept (PoC) clinical trial of AK3280 in the United States. The Phase 2 study is a multi-center, randomized, partially double-blind, placebo- and active-controlled trial designed to evaluate the
- 김갑성 기자
- 2026-02-12 12:18
WuXi Vaccines Receives Brazil's ANVISA GMP Certification

SUZHOU, China, Feb. 12, 2026 -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish facility (DP17) in Suzhou from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The facility is providing integrated manufacturing services for Instituto Butantan's dengue vaccine (Butantan-DV) production project. Following comprehensive on-site inspections of DP17, a commercial
- 김갑성 기자
- 2026-02-12 11:48
Australia and New Zealand's Skin Cancer Governance Gap Exposed: 40% of Organisations Never Assessed Workforce Risk Despite 84% Believing Duty of Care Applies

SYDNEY, Feb. 12, 2026 -- A comprehensive new report on workplace skin cancer screening in Australia and New Zealand has exposed a significant governance blind spot: whilst 84% of organisations believe skin checks should be part of their duty of care, 40% have never assessed their workforce's skin cancer risk, and 23% of boards don't understand UV exposure as a workplace health and safety concern. The research, drawn from MoleMap's analysis of 48,000+ workplace skin checks and a survey of 410 HR and wellbeing managers across ANZ, reveals a disconnect between awareness and action that pu
- 황정호 기자
- 2026-02-12 10:32

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 01시 00분